Vaxdyn develops multi‑pathogen vaccine candidates aimed at preventing infections caused by antibiotic‑resistant bacteria. Headquartered in Seville, Spain, the company works with an international network of collaborators to target high‑risk populations (chronic lung, liver, kidney disease, immunocompromised patients, nursing‑home and hospital settings). Its vision is to create specific immunity in these groups and to reduce antibiotic use worldwide following a One‑Health approach. Recent financing activity includes share acquisitions by Bionova Capital and Arquimea Group (each valued at €300,000 in two tranches) and a €100,000 capital increase from the Mind the Gap Program. Vaxdyn also benefits from CARB‑X support: up to $7.3 million in non‑dilutive, milestone‑based funding to advance its lead vaccine candidate through a first‑in‑human study. Strategic investors are positioned to contribute sector expertise and cross‑sector technological support to the company’s vaccine development efforts.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2021